Volume 4, Issue 3 (Aug 2016)                   Res Mol Med (RMM) 2016, 4(3): 41-46 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Poopak B, Heidari M, Fallah P, Safari N, Rabieipoor S, Amiri Z et al . Genetic Polymorphisms of CYP2C19 and Resistance to Clopidogrel Therapy among Iranian Patients Suffering from Ischemic Heart Disease. Res Mol Med (RMM) 2016; 4 (3) :41-46
URL: http://rmm.mazums.ac.ir/article-1-195-en.html
1- Islamic Azad University, Tehran Medical Sciences Branch , bpoopak@gmail.com
2- Islamic Azad University, Tehran Medical Sciences Branch
3- Alborz University of Medical Sciences
4- Payvand Clinical and Specialty Laboratory
5- Department of Hematology, Islamic Azad University, Tehran Medical Sciences Branch, Tehran, Iran
Abstract:   (31293 Views)

Background: Clopidogrel is a standout amongst the most ordinarily recommended medications to avoid ischemic occasions taking after coronary disorder or stant position. However, impaired responses the therapy as well as resistance to the therapy have also been reported. Genetic variants play an important role in clopidogrel biotransformation of its active metabolite that may subsequently influence the antiplatelet effect of clopidogrel. The objective of this study was to evaluate the prevalence of the cytochrome P450 (CYP450) 2C19 enzyme (CYP2C19) genotypes which are involved in the activation of clopidogrel in a random Iranian population of various ethnic groups (Persian, Azari, Kurd, etc.). Molecular analysis of CYP2C19 polymorphisms may be helpful in the determination of optimal antiplatelet therapy.

Materials and Methods: CYP2C19 (*1/*2/*3) variants were assessed by Polymerase Chain Reaction-Restriction Length Polymorphism (PCR–RFLP) assays in a representative sample of 154 Iranian patients with ischemic heart disease.

Results: The frequencies of CYP2C19 *1 (normal genotype), *2 (heterozygote) and *3 (homozygote) were 112 (72.7%), 36 (23.4%) and 6 (3.9%), respectively.

Conclusion: The United States Food and Drug Administration (FDA) recommendations are more useful to be practiced in our country compared with other countries. Physicians should identify poor metabolizers for consideration of other antiplatelet medications or alternative dosing strategies.

Full-Text [PDF 450 kb]   (2824 Downloads)    
Type of Study: Research | Subject: Molecular biology
Published: 2016/08/21

Add your comments about this article : Your username or Email:

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.


Designed & Developed by : Yektaweb